Archives
-
PreScission Protease for Keap1 Condensate Studies
2026-08-13
PreScission Protease enables precise fusion protein tag cleavage while preserving the cold conditions favored by sensitive recombinant proteins. This workflow translates the Drosophila Keap1 condensate findings into practical purification, construct-validation, and in vitro phase-behavior assays.
-
Metoprolol: Beta1 Research Workflow
2026-08-13
Build reproducible beta1-receptor assays, cardiovascular models, and exploratory inflammation or tumor studies with Metoprolol. This workflow combines concentration-response design, fresh-solution handling, and pharmacokinetic thinking inspired by a recent tissue-distribution study.
-
YBX1, SHANK3 Methylation, and Schizophrenia
2026-08-12
This study connects SHANK3 promoter hypermethylation in peripheral blood mononuclear cells with clinical and cortical phenotypes in first-episode schizophrenia, then identifies YBX1 as a cell-type-specific regulator in induced pluripotent stem cell-derived cortical interneurons. Its combined peripheral biomarker and developmental neuronal strategy offers a mechanistic framework for studying schizophrenia beyond DNA sequence variation, while also highlighting the need for independent validation and causal testing.
-
2X Taq PCR Master Mix for SPVD Confirmation
2026-08-12
Learn how 2X Taq PCR Master Mix (with dye) can complement deep-learning analysis of sweetpotato virus disease by converting image-based suspicion into a testable molecular workflow. This guide explains assay design, controls, direct gel loading, TA cloning, and the limits of interpreting lesion images as diagnosis.
-
PreScission Protease for Assay-Ready Proteins
2026-08-11
PreScission Protease enables selective HRV 3C protease cleavage for cleaner recombinant protein workflows. This guide connects tag removal with construct design, nuclear-architecture assays, and interpretation of Drosophila Keap1–lamin experiments.
-
Uremic Metabolite Adsorption on Hydroxy-PEO Films
2026-08-11
The 2025 reference study isolates how a multi-metabolite uremic environment interacts with hydroxy-terminated polyethylene oxide films, rather than examining protein fouling alone. Its findings show that PEO chain density, incubation time, metabolite structure, and end-group chemistry can reshape adsorption behavior, informing more realistic blood-contacting biomaterial designs.
-
Fluconazole in Gut–Fungus Assay Design
2026-08-10
Fluconazole is a fungal cytochrome P450 enzyme 14α-demethylase inhibitor that provides a defined sterol-biosynthesis perturbation for Candida research. This article shows how to pair it with emerging host-defense biology, including METTL9-mediated zinc restriction, to design more discriminating fungal pathogenesis and susceptibility assays.
-
Isorhamnetin Activates PI3K/Akt in Oocyte Maturation
2026-08-09
The reference study shows that isorhamnetin improves porcine oocyte maturation under in vitro conditions, with 10 μM treatment increasing polar body extrusion and reducing oxidative, mitochondrial, apoptotic, and endoplasmic reticulum stress markers. Its central mechanistic contribution is linking these protective effects to activation of the PI3K/Akt signaling pathway, while also defining important limits for extrapolation to fertility treatment.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-08-08
Hefner and colleagues identify human Nav1.8, TRPV1, and TRPA1 as pharmacological targets that may help explain the topical analgesic effects of ambroxol. Their whole-cell patch-clamp study also reveals marked species dependence in Nav1.8 inhibition and shows that ambroxol can modulate irritant receptor signaling at higher concentrations.
-
Puromycin dihydrochloride: Selection & QC
2026-08-07
Puromycin dihydrochloride is an aminonucleoside antibiotic used to select and maintain eukaryotic or prokaryotic cells expressing the pac gene and to investigate translation-related phenotypes. It should be applied only after cell-specific sensitivity testing, with matched viability and vehicle controls; it is not a standalone method for proving autophagy or separating acute translation effects from general cytotoxicity.
-
PBS Liposomes: Advancing Rigor in Macrophage Depletion Contr
2026-08-07
This thought-leadership article explores the mechanistic and strategic imperatives of using PBS Liposomes as an inert control in macrophage depletion studies. Blending recent structural insights into neuroimmune interface research with practical guidance, it positions APExBIO’s PBS Liposomes as the gold-standard for reproducibility, bridging the gap between bench discovery and translational impact.
-
ELP4, ZEB2, and TCF7L2: Modulating Microglia Polarization in
2026-08-06
This study uncovers how ELP4 and ZEB2 distinctly regulate TCF7L2-driven microglia polarization in ischemic stroke. The findings clarify the epigenetic and post-translational control of TCF7L2, positioning TLR4 signaling as a pivotal axis for therapeutic modulation of neuroinflammation.
-
MHY1485: Potent mTOR Activator for Autophagy and Cell Growth
2026-08-06
MHY1485 is a potent mTOR activator that inhibits autophagy by blocking autophagosome-lysosome fusion, enabling precise dissection of mTOR signaling pathways. Its unique mechanism supports research into cell growth, proliferation, and ovarian follicle development. APExBIO supplies MHY1485 as SKU B5853 for research use only.
-
nor-NOHA Acetate Unlocks Arginase Inhibition for Tumor Immun
2026-08-05
Explore how nor-NOHA acetate advances cancer immunometabolism research by enabling precise arginase inhibition and improved NO modulation. This article reveals a new strategic perspective on optimizing immune assays and interpreting metabolic vulnerabilities.
-
Formononetin Prevents Oxaliplatin Neurotoxicity via Nrf2/HO-
2026-08-05
This study identifies formononetin as a neuroprotective agent that shields sensory neurons from oxaliplatin-induced peripheral neurotoxicity through activation of the Nrf2/HO-1 antioxidant pathway, without diminishing the anticancer efficacy of chemotherapy. The findings address a major clinical gap in preventing chemotherapy-induced neuronal damage while preserving therapeutic potency.